USE OF SALINOSPORAMIDE A TO INHIBIT METASTASIS
The present invention relates to methods and compositions for treating and evaluating metastatic conditions.
1 . A method for inhibiting metastasis in a subject having a metastatic condition, comprising:
identifying a subject experiencing or at risk for metastasis; and
administering to the subject an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt or pro-drug ester thereof, wherein the compound of Formula I has the structure:
2 . The method of claim 1 , wherein said metastatic condition is selected from the group comprising prostate cancer, lung cancer, breast cancer, melanoma, colon cancer, kidney cancer, and pancreatic cancer.
3 . The method of claim 1 , wherein said metastatic condition comprises prostate cancer.
4 . The method of claim 1 , wherein said compound of Formula I is administered in combination with an effective amount of an additional anticancer agent.
5 . The method of claim 4 , wherein said additional anticancer agent is selected from the group comprising vincristine, cis-diamminedichloridoplatinum(II) (CDDP), Tumor necrosis (TNF)-related apoptosis-inducing ligand (TRAIL), and agonist antibody to DR4 or DR5.
6 . The method of claim 1 , wherein said subject is a mammal.
7 . The method of claim 1 , wherein said subject is human.
8 . A method for evaluating the metastatic potential of a cancer comprising measuring the expression level of at least one marker in a sample from a subject afflicted with said cancer, wherein said at least one marker is selected from RKIP, Snail, NF-κB, E-cadherin, cytokeratin 18, fibronectin, and vimentin.
9 . The method of claim 8 , wherein said measuring the expression level of at least one marker comprises measuring the expression level of a nucleic acid.
10 . The method of claim 8 , wherein said measuring the expression level of at least one marker comprises measuring the expression level of a protein.
11 . The method of claim 8 , further comprising comparing said expression level of said at least one marker in said sample to the expression level of said at least one marker in normal tissue, tissue from a known stage of cancer, or cancerous tissue with a known metastatic potential.
12 . The method of claim 11 , wherein said at least one marker comprises RKIP.
13 . The method of claim 12 , wherein said at least one marker comprises Snail.
14 . The method of claim 12 , wherein a decrease in the expression level of said RKIP indicates the metastatic potential of said cancer.
15 . The method of claim 11 , wherein said at least one marker comprises at least three markers.
16 . The method of claim 11 , wherein said at least one marker comprises at least four markers.
17 . The method of claim 11 , wherein said at least one marker comprises at least five markers.
18 . The method of claim 11 , wherein said at least one marker comprises at least six markers.
19 . The method of claim 11 , further comprising administering to the subject an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt or pro-drug ester thereof, wherein the compound of Formula I has the structure: